Del Giudice Matthew Paul 4

What Happened
Matthew Paul Del Giudice, a director of Mira Pharmaceuticals, was granted 50,000 stock options on June 12, 2026. The Form 4 lists the acquisition as a derivative grant with a reported dollar amount of $0.00 because the option exercise price equals the closing market price on the grant date ($0.94 per share).

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026 (timely within required business-day window).
• Grant: 50,000 stock options, exercise price $0.94 per share (F1, F3). Form reports acquisition value $0.00.
• Vesting: 50% vests on the six-month anniversary and the remaining 50% vests on the one-year anniversary of the grant date (F2, F3).
• Plan: Issued under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (F2).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Reported on 2026-06-15 for a 2026-06-12 grant; this filing date is within the usual two-business-day Form 4 deadline.

Context
This was a standard option grant to a director, not an exercise or sale. Because the exercise price matches the market close on the grant date, the options had no intrinsic value at issuance (hence $0 reported). Options will only have economic value if the stock rises above $0.94 before or at exercise.